DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Contactexpress Faqs Legends Search Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | AliX | Alizé Pharma | Alphelys | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Atlantic Bone Screen | Aureus Pharma | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | BioMedical Diagnostics | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-modeling) | BT Pharma | Carmat | Cellectis | Cellial Technologies | CellVax | CellVir | Cerenis Therapeutics | Cezanne | CliniGenetics | Covalab | Cytheris | Cytomics | Cytoo | DBV Technologies | DNA Therapeutics | Domain Therapeutics | Dynabio | EchoSens | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Exonhit | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | GenOdyssee | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | GTP Technology | Helios Biosciences | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences (AbAg) | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | LibraGen | Magnisense | Mapreg | MAT Biopharma | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MicroBioChips | MilleGen | MitoProd | Murigenetics | Mutabilis | Myosix | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NicOx | Nokad | Nosopharm | Nova Decision | Novagali | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharmaxon | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | PraXcell | Proteogenix | Protéus | Protexel | PX’Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sepal Pharma | Serial Genetics | Sisène Biotechnologies | Skuld-Tech | Synapcell | Synprosis | Tc Land Expression | Theraclion | TheraVectys | Transgene | Trophos | TxCell | UroGene | UROsphere | Urrma | Vaxon Biotech | Vectalys | VigiCell | Vivalis | XenTech | Zeta Biotech |

* ERYTECH PHARMA *


2004 - Rhône-Alpes
Lyon
www.erytech.com

Delivery, Drugs
Key words: Encapsulation, Red blood cells, Cancer, Cleav'Ery, Oxygen'Ery, Deliv'Ery, Vaccin'Ery, Graspa
Mission: to develop the encapsulation of therapeutic molecules or enzymes into red blood cells in order to improve the therapeutic index, notably in orphan indications or underserved subpopulation of higher risk patients
Clients: Prescribers
contact@erytech.com

Age: 5 year(s)

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Godfrain (Yann) [co-founder, born 1970, Ph.D., Biomedical Eng., ex-BioAlliance Pharma, Hemosystem, Hemoxymed]
Oper.Dir.: Goineau (Pierre-Olivier) [co-founder, born 1967, ex-KPMG]
Sc.Dir.-CSO: Godfrain (Yann)
Med.Dir.: Liens (David) [M.D., ex-Merck (KgaA)
Fin.Dir.-CFO: Dujardin (Philippe) [Ms. finance, ex-Atari, Suez-Lyonnaise des Eaux]
BusDev: Bouvier (Maud) [Sup de Co (Grenoble)]
Financers (Hist.): AXA P.E., Auriga Partners, AGF P.E., Capdecisif, Créalys

Turnover (M€) : n.a.
Total funding (M€) : 13.0
Last funding (M€) : 12.0
Focus : Cancers
Position : Clinical
Company confirm : none

History
DATEMILESTONETYPETIME
2010 .01 Registration : orphan Drug designation by FDA for GRASPA MKTG [5 years]
2009 .01 Partnering R&D agreement with American Red Cross to produce Graspa for clinical trials in USA R&D [4 years]
2008 .10 Clinical trial (phase II) for new vaccine concept against cancer, based on red blood cells, Vaccin’ERY (completed, positive) CLIN [3 years]
2008 .05 Clinical trial (phase II) for Graspa (orphan drug) in leukemia (completed) CLIN [3 years]
2006 .11 1st round-financing : 12.0 M€, by AXA P.E., Auriga Partners, AGF P.E., Capdecisif RFINA [2 years]
2006 .06 Registration : orphan Drug designation by EMEA for GRASPA MKTG [1 year]
2005 .11 Clinical trial (phase II) for lead compound in leukemia (beginning) CLIN [1 year]
2005 .10 Seed financing : 0.75 M€, by Amorçage Rhône Alpes (+ 0.45 M€ from contest by French Ministry of R&D) SFIN [0 year]
2004 .11 Company founded by Yann Godfrin and Pierre-Olivier Goineau ORGF [0 year]

Actualisation / Updating: 05-Feb-2010


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT
Pour retourner à la page d'accueil Biotech: BIENVENUE !

Haut de page :

Copyright J.H. Huber, Pharmaclient 2001-2010.

Pharmaclient, le site de la valorisation client en Pharma, est la vitrine des activités de conseil de Jean Huber: Stratégie, Communication, Relation Client en Pharma.